Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Real-Time Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
RTNominal unchange 0.000 (0.000%)

27/08/2019 10:38

Fosun Pharma (02196) interim net down 3% to RMB1.52bn

[ET Net News Agency, 27 August 2019] Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
(02196) said its profit attributable to owners of the parent was RMB1.52 billion for the
six months ended 30 June 2019, a year-on-year decrease of 2.84%. The earnings per share
were RMB0.59. No dividend will be distributed.
The revenue was RMB14.09 billion, a year-on-year increase of 19.71%. The gross profit
was RMB8.49 billion, a year-on-year increase of 24.42%. (RC)

Remark: Real time quote last updated: 07/04/2020 07:53
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2020 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.